A Revolution in
Eye Disease Treatment

At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

He also oversees the preclinical and clinical development of each of the company’s products. In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs. David received a BS in Microbiology from the University of Maryland and an MD from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.

In this role, Ms. Bauerlein oversaw the global finance and accounting functions, including revenue management, financial planning and analysis, strategic and tactical cost analysis and forecasting, treasury, SEC reporting, investor relations, business development, risk management, tax, and treasury functions, as the Inogen scaled from start-up operations to over $350 million in annual sales. Ali has also served as a member of the board of directors of Pear Therapeutics, Inc, a software-based digital therapeutics company, since December 2021, and as a member of the board of directors of Gelesis Holdings, Inc, a biotherapeutics company since January 2022. She serves as chair of the Audit Committees of both Pear and Gelesis. Ms. Bauerlein also serves as a member of the board of directors of Koya Medical, Inc., a private company, since January 2021. Ali received a B.A. in economics/mathematics with high honors from the University of California, Santa Barbara.

He has been in practice in Atlanta since 1988. Dr. Brown has published more than 90 peer reviewed articles on glaucoma and cataract surgery. He has served as chairman of the ASCRS Glaucoma Committee and is currently the Glaucoma Editor of EyeWorld magazine. He recently received the Senior Achievement Award from the American Academy of Ophthalmology. Dr. Brown is one of only a few ophthalmologists in Georgia to receive this prestigious award. He received the 2013 Distinguished Alumnus Award from John Hopkins University (Wilmer Eye Institute) and the 2014 Innovator Award form the American Glaucoma Society. He has given many named lectures all over the world including the Obstbaum Lecture at the 2011 ASCRS Glaucoma Day. He was selected to give the Charles D. Kelman Innovator Lecture in 2017. This international award honors Dr. Kelman, the inventor of phacoemulsification, a huge step forward in successful cataract surgery outcomes. This award has only been given to 33 innovators in eye surgery since its inception in 1985.

Dr. Brown and his wife, Dr. Mary G. Lynch, a Professor at Emory, have been awarded 25 patents for new devices and instruments to improve glaucoma and cataract surgery. Their patents on trabecular bypass are the fundamental patents for several innovative devices implanted into the outflow channel of the eye. Dr. Brown has been selected by his peers to be listed each year in Best Doctors in America and by a separate peer survey in Atlanta Magazine as one of the best ophthalmologist in Atlanta.

Dr. Brown earned his undergraduate degree from Harvard College Cum laude and completed medical school at the University of Michigan. He trained in ophthalmology at the Wilmer Eye Institute of Johns Hopkins University. He then completed a glaucoma fellowship at the Bascom Palmer Eye Institute and returned to Johns Hopkins as Chief Resident.

Dr. Brown was selected as the first Pamela Firman Professor of Ophthalmology at the Emory Eye Center. Mrs. Firman made the donation for the professorship in gratitude for Dr. Brown’s care of her eyes. He served as the Director of the Glaucoma Service at Emory for eleven years prior to entering private practice with Atlanta Ophthalmology Associates in 1999.

Drs. Brown and Lynch have two daughters, Veronica and Annie. Rounding out their household is, Lily, a loving English Mastiff. Dr. Brown is an avid runner, enjoys playing tennis and traveling with his family.

Before Orion, Mr. Link spent nearly 15 years in regional and executive leadership positions at NuVasive Inc., a global leader in surgical implants and enabling technology for spine surgery and orthopedics, where he designed and executed strategies that supported the company’s revenue growth from less than $100 million to over $1 billion. Mr. Link joined NuVasive as an Area Business Manager and rose to the level of President where his responsibilities included oversight of global business units in spine, neurophysiology and orthopedics. Prior to NuVasive, Mr. Link held commercial leadership roles at Depuy Orthopedics and Depuy Spine. He currently serves as a member of the board of directors of Springbok Analytics, Fibrobiologics and DinamicOR. Additionally, he serves on the board of directors for the Coulter Translational Research Endowment at the University of Virginia. Mr. Link received a BSEd in Physical Education and Sports Medicine from the University of Virginia.

Since 2012, Jeremy has worked exclusively in senior legal positions for innovative medical device companies, including serving as Assistant General Counsel for Volcano Corporation, General Counsel and Vice President of Business development for Cytori Therapeutics, Inc. and General Counsel for Endologix, Inc. Jeremy holds a J.D. from University of Michigan Law School and an A.B. in Politics from Princeton University.

He also led operations at Novacept from early revenue to its acquisition by Cytyc. Sam has held various other executive and technical positions at Spineview (Expending Innovation), Arthrocare (acquired by Smith and Nephew), CardioGenesis (IPO), and Origin Medsystems (acquired by Eli Lily, later Guidant).

Before entering the medical device industry, Sam worked in aerospace at Hughes Aircraft, and Xerox Designing and Manufacturing Laser Systems.
Sam hold a BS from the University of California Irvine in Mechanical Engineering.